Table 2.
Hepatic, lipid, and renal profile before and 3 months after the addition of a CBD-enriched extract to insulin treatment
| Analyte | Value before oil treatment | Three months after oil treatment | Normal range in felines |
|---|---|---|---|
| Hepatic profile | |||
| GPT (ALT) alanine aminotrasferase or glutamic pyruvic transaminase | 57 | 58 | <80 U/L |
| GOT (AST) aspartate aminotransferase or glutamic-oxaloacetic transaminase | 20 | 20 | <70 U/L |
| GGT gamma-glutamyltransferase | 5 | – | 0–10 U/L |
| Total protein | 7.2 | 8.3 | 5.6–7.8 g/dL |
| Albumin | 3.58 | 3.7 | 2.1–3.6 g/dL |
| Globulin | – | 4.6 | 3–4 g/dL |
| Albumin/globulin ratio | 0.9 | – | 0.5–1.3 |
| ALP (alkaline phosphatase) | 62 | 87 | <100 U/L |
| Total bilirubin | 0.14 | 0.01 | 0–0.6 mg/dL |
| Direct bilirubin | 0.00 | 0.00 | 0–0.3 mg/dL |
| Indirect bilirubin | 0.14 | – | |
| Glucose | 76 | 83 | 70–110 mg/dL |
| Lipid profile | |||
| Cholesterol | 184 | 289 | 0–150 mg/dL |
| Triglyceride levels | 47 | 100 | 50–100 mg/dL |
| HDL cholesterol | – | 200 | >100 mg/dL |
| LDL cholesterol | – | 69 | <60 mg/mL |
| Renal profile | |||
| Creatinine | 2.34 | 2.9 | <1.5 mg/dL |
| Urea | 66 | 114 | 30–60 mg/dL |
| Phosphorus | 4.6 | 4.8 | 2.6–6 mg/dL |
All parameters remained below the reference levels, suggesting that CBD-dominant extract administration via oromusosal, each 12 h (BID) during this period, was safe.